CVS Health Earnings Reports

CVS Health saw solid financial and operational performance in Q1 2025, with notable gains in adjusted EPS and net income, boosted by improvements in its Health Care Benefits segment and expanded access initiatives across the enterprise.

CVS Health reported Q4 2024 revenue of $97.71 billion, up 4.2% YoY, but experienced a decline in operating income and net income due to pressures in the Health Care Benefits segment. GAAP EPS fell to $1.30 from $1.58, and Adjusted EPS dropped to $1.19 from $2.12.

CVS Health's total revenues for the third quarter increased by 6.3% to $95.4 billion. GAAP diluted EPS was $0.07, and adjusted EPS was $1.09. The results were impacted by charges related to premium deficiency reserves in the Health Care Benefits segment.

CVS Health reported a 2.6% increase in total revenues for the second quarter of 2024, reaching $91.2 billion. However, GAAP diluted EPS decreased to $1.41, and Adjusted EPS decreased to $1.83, primarily due to declines in the Health Care Benefits segment. The company has revised its full-year 2024 guidance to reflect continued pressure in the Health Care Benefits segment, partially offset by strong performance in the Health Services and Pharmacy & Consumer Wellness segments.

CVS Health's Q1 2024 results showed revenue growth but a decline in profitability due to increased Medicare utilization. The company has revised its full-year guidance to reflect these challenges.

CVS Health's Q4 2023 total revenues increased to $93.8 billion, up 11.9% compared to prior year. GAAP diluted EPS was $1.58 and Adjusted EPS was $2.12.

CVS Health reported a 10.6% increase in total revenues, reaching $89.8 billion, driven by growth across all segments. GAAP diluted EPS was reported at $1.75, and adjusted EPS at $2.21. The company is adapting to changing consumer needs by connecting care delivery capabilities and broadening access to affordable health and wellness services.

CVS Health reported a 10.3% increase in total revenues to $88.9 billion for Q2 2023, driven by growth across all segments. GAAP diluted EPS was $1.48, and adjusted EPS was $2.21. The company is executing its strategy to expand access to health services and strengthen consumer engagement.

CVS Health reported a strong first quarter with total revenues increasing by 11.0% to $85.3 billion. GAAP diluted EPS was $1.65, and Adjusted EPS was $2.20. The company generated $7.4 billion in cash flow from operations and completed the acquisitions of Signify Health and Oak Street Health.

CVS Health's Q4 2022 results showed a total revenue increase of 9.5% to $83.8 billion and a GAAP diluted EPS of $1.75. The company's performance was driven by growth across all segments.

CVS Health reported a revenue increase of 10.0% to $81.2 billion. However, the company experienced a GAAP loss per share of $(2.60) due to significant charges, including $5.2 billion for opioid litigation and $2.5 billion related to the Omnicare long-term care business. Despite the loss, the adjusted EPS was $2.09.

CVS Health's total revenues increased to $80.6 billion, up 11.0% compared to prior year. GAAP diluted EPS was $2.23 and Adjusted EPS was $2.40. The company raised its full-year 2022 GAAP diluted EPS guidance range to $7.23 to $7.43 from $6.93 to $7.13 and raised its full-year 2022 Adjusted EPS guidance range to $8.40 to $8.60 from $8.20 to $8.40. The company also raised its full-year 2022 cash flow from operations guidance range to $12.5 billion to $13.5 billion from $12.0 billion to $13.0 billion.

CVS Health reported a strong first quarter with total revenues increasing by 11.2% to $76.8 billion. GAAP diluted EPS was $1.74, and adjusted EPS was $2.22. The company generated $3.6 billion in cash flow from operations and raised its full-year adjusted EPS guidance.

CVS Health's Q4 2021 total revenues increased to $76.6 billion, up 10.1% compared to the prior year. GAAP diluted EPS was $0.98, and adjusted EPS was $1.98. The company administered over 8 million COVID-19 tests and 20 million vaccines in Q4 2021.

CVS Health reported strong Q3 2021 results with total revenues increasing to $73.8 billion, GAAP diluted EPS of $1.20, and adjusted EPS of $1.97.

CVS Health announced strong Q2 2021 results with total revenues increasing to $72.6 billion, up 11.1% compared to the prior year. The company raised its full year EPS and cash flow from operations guidance.

CVS Health announced strong Q1 results, with total revenues increasing to $69.1 billion, a 3.5% increase compared to the prior year. GAAP diluted EPS was $1.68, up 9.8% year-over-year, and adjusted EPS was $2.04, reflecting a 6.8% increase. The company generated a cash flow from operations of $2.9 billion and raised its full-year EPS guidance.

CVS Health's Q4 2020 results reflected COVID-19 impacts and related investments. Full year total revenues increased to $268.7 billion, up 4.6% compared to prior year. The company utilized its capabilities and community presence for COVID-19 testing and vaccine administration.

CVS Health reported a 3.5% increase in total revenues to $67.1 billion, GAAP diluted earnings per share of $0.93, and adjusted EPS of $1.66. The company raised its full-year 2020 EPS and cash flow from operations guidance ranges.

CVS Health reported a 3.0% increase in total revenues, reaching $65.3 billion. GAAP operating income increased by 40.5% to $4.7 billion, and adjusted operating income increased by 32.2% to $5.3 billion. GAAP diluted earnings per share was $2.26, and adjusted EPS was $2.64.

CVS Health reported an 8.3% increase in total revenues to $66.8 billion and a 28.6% increase in GAAP operating income to $3.5 billion. Adjusted EPS was $1.91, and the company generated $3.3 billion in cash flow from operations. 2020 full year EPS guidance remains unchanged.

CVS Health's Q4 2019 revenues increased by 22.9% to $66.9 billion, GAAP operating income increased to $3.0 billion, and adjusted operating income increased by 1.3% to $3.8 billion. GAAP diluted earnings per share from continuing operations were $1.33, and adjusted EPS was $1.73. The company's performance reflects strong financial and operational execution and a successful first year of integrating the Aetna business.